Novo Nordisk/$NVO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Novo Nordisk
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Ticker
$NVO
Sector
Primary listing
NYSE
Employees
78,387
Headquarters
Bagsvaerd, Denmark
Website
Novo Nordisk Metrics
BasicAdvanced
$254B
14.54
$3.92
0.27
$1.18
2.87%
Price and volume
Market cap
$254B
Beta
0.27
52-week high
$137.85
52-week low
$45.05
Average daily volume
22M
Dividend rate
$1.18
Financial strength
Current ratio
0.784
Quick ratio
0.505
Long term debt to equity
51.947
Total debt to equity
59.065
Dividend payout ratio (TTM)
45.63%
Interest coverage (TTM)
17.27%
Profitability
EBITDA (TTM)
25,005.57
Gross margin (TTM)
84.26%
Net profit margin (TTM)
35.61%
Operating margin (TTM)
47.65%
Effective tax rate (TTM)
21.10%
Revenue per employee (TTM)
$624,890
Management effectiveness
Return on assets (TTM)
21.82%
Return on equity (TTM)
79.17%
Valuation
Price to earnings (TTM)
14.543
Price to revenue (TTM)
5.174
Price to book
9.62
Price to tangible book (TTM)
26.86
Price to free cash flow (TTM)
26.198
Free cash flow yield (TTM)
3.82%
Free cash flow per share (TTM)
2.175
Dividend yield (TTM)
2.07%
Forward dividend yield
2.87%
Growth
Revenue change (TTM)
20.90%
Earnings per share change (TTM)
24.26%
3-year revenue growth (CAGR)
25.65%
10-year revenue growth (CAGR)
12.15%
3-year earnings per share growth (CAGR)
31.20%
10-year earnings per share growth (CAGR)
15.33%
3-year dividend per share growth (CAGR)
27.85%
10-year dividend per share growth (CAGR)
16.64%
What the Analysts think about Novo Nordisk
Analyst ratings (Buy, Hold, Sell) for Novo Nordisk stock.
Novo Nordisk Financial Performance
Revenues and expenses
Novo Nordisk Earnings Performance
Company profitability
Novo Nordisk News
AllArticlesVideos
Eli Lilly's obesity pill remains a viable rival to Novo's oral Wegovy despite data that underwhelmed investors
CNBC·1 day ago
Fat busters having a muted impact consumer sector. But for how long?
Proactive Investors·4 days ago
Riding high on Wegovy, Novo doubled its workforce. Now layoffs loom
Reuters·4 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Aug26
Novo Nordisk
Dividend·Payment
$0.58432Per share
FAQs
What’s the current market cap for Novo Nordisk stock?
Novo Nordisk (NVO) has a market cap of $254B as of August 25, 2025.
What is the P/E ratio for Novo Nordisk stock?
The price to earnings (P/E) ratio for Novo Nordisk (NVO) stock is 14.54 as of August 25, 2025.
Does Novo Nordisk stock pay dividends?
Yes, the Novo Nordisk (NVO) stock pays dividends to shareholders. As of August 25, 2025, the dividend rate is $1.1814 and the yield is 2.87%. Novo Nordisk has a payout ratio of 45.63% on a trailing twelve-month basis.
When is the next Novo Nordisk dividend payment date?
The next Novo Nordisk (NVO) dividend payment is scheduled for August 26, 2025.
What is the beta indicator for Novo Nordisk?
Novo Nordisk (NVO) has a beta rating of 0.27. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.